The triple-receptor peptide whose Phase 2 obesity trial reported a mean weight reduction of around 24% at 48 weeks. Pre-loaded, independently tested, cold-chain delivered across Europe.
Retatrutide is a single peptide that activates three metabolic receptors at once: GLP-1, GIP and glucagon. Most weight-management peptides act on one or two of these. Acting on all three is why it has drawn so much attention.
In practice those three levers do different jobs: GLP-1 slows gastric emptying and reduces appetite, GIP supports insulin sensitivity and appears to improve tolerability, and glucagon-receptor activation increases energy expenditure. The result is appetite suppression paired with higher energy expenditure, rather than appetite suppression alone.
Retatrutide is an investigational compound. The figures below come from published, peer-reviewed clinical trials of the compound. They are not claims about Body Pharm's product, and individual results vary.
A separate Phase 2 trial in adults with type 2 diabetes reported a mean weight reduction of roughly 16.9% at 36 weeks (Rosenstock J, et al. Lancet. 2023;402(10401):529–544).
Trial participants received the investigational formulation under clinical supervision, alongside diet and exercise counselling. Retatrutide is not approved by the EMA or FDA. These results describe the compound in research settings and are not a promise of outcome.
Before-and-after photos shared with permission by our customers on their own retatrutide protocol.
−18 kg 
−16.8 kg 
−9 kg 
−24 kg 
Reached goal 
−22.5 kg Photos shared with consent by customers of our UK store. Each result reflects that person's full programme — diet and activity alongside the compound, under clinician guidance. Retatrutide is an investigational compound; individual results vary and are not typical or guaranteed.
Both pens hold 3 ml of the same compound. The 64 mg pen holds double the peptide in the same volume, which lowers the cost per milligram.
The smaller commitment
The smaller pen, if you would rather begin with less peptide on hand. Your clinician sets the dose; the pen does not.
Best value per mg
The 64 mg pen holds twice the peptide in the same 3 ml and brings the price per milligram down.
No vials, no bacteriostatic water, no dosing maths. Dial your dose, press, done: the same format used in modern diabetes care.
An independent laboratory tests every batch for identity, purity and sterility before it ships. Scan the QR code on your pen for the certificate of analysis for your exact lot.
Insulated packaging with a cooling element and a temperature indicator holds 2–8 °C from our Czech dispatch point to your door. Orders placed before 12:00 on a business day dispatch the same day; delivery takes 3–5 business days.
Five pens take 10% off and ten pens take 15% off, applied automatically at checkout and pooled across compounds.
Semaglutide is a single agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds a third receptor, glucagon, which is associated with increased energy expenditure on top of appetite reduction. That third receptor is the usual explanation for why its Phase 2 weight-reduction figures came in higher than those reported for the earlier compounds.
The 32 mg pen holds 32 mg in 3 ml; the 64 mg pen holds 64 mg in 3 ml. How long a pen lasts depends entirely on the weekly dose your clinician sets. The trial protocols ran from 1 mg up to 12 mg weekly with titration every four weeks, so a pen's duration changes as the dose changes.
No. Retatrutide is an investigational compound still in clinical development and is not approved by the EMA or FDA. It should only be used under the supervision of a qualified clinician, who should set your dose and monitor your bloodwork.
The Phase 2 trial reported that the most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting and constipation), generally mild to moderate and dose-related. Slow titration is the standard approach to reducing them. Discuss your full medical history with your clinician before starting.
Pens are temperature-sensitive and ship in insulated cold-chain packaging held between 2 and 8 °C. Refrigerate on arrival. If a pen arrives broken or isn't working, we replace it free of charge once you share photos or a short video showing the fault.
Yes. Ordering and joining a waitlist both require an account, and ordering also requires the eligibility quiz. Your order history lives in your account; the certificate for your batch is reached from the QR code on the pen or from the certificate index.
Both strengths ship cold-chain with a batch certificate of analysis. Bulk pricing applies automatically.
Choose your penEducational content only — not medical advice. Retatrutide is an investigational compound not approved by the EMA. Peptide protocols should be run under the supervision of a qualified clinician. These statements have not been evaluated by the EMA.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy